These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 37532423)

  • 21. Updated network meta-analysis assessing the relative efficacy of 13 GLP-1 RA and SGLT2 inhibitor interventions on cardiorenal and mortality outcomes in type 2 diabetes.
    Qiu M; Wei W; Wei XB; Liu SY
    Eur J Clin Pharmacol; 2022 Apr; 78(4):695-697. PubMed ID: 34860262
    [No Abstract]   [Full Text] [Related]  

  • 22. SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes: BMJ Rapid Recommendation.
    Arnold MJ; Buelt A
    Am Fam Physician; 2022 Jun; 105(6):675-677. PubMed ID: 35704807
    [No Abstract]   [Full Text] [Related]  

  • 23. Effect of novel glucose lowering agents on non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Zafar Y; Rashid AM; Siddiqi AK; Ellahi A; Ahmed A; Hussain HU; Ahmed F; Menezes RG; Siddiqi TJ; Maniya MT
    Clin Res Hepatol Gastroenterol; 2022; 46(7):101970. PubMed ID: 35659603
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In type 2 diabetes, SGLT2 inhibitors reduce all-cause, but not cardiovascular, mortality vs. GLP-1 RAs.
    Tanner M
    Ann Intern Med; 2021 Jun; 174(6):JC67. PubMed ID: 34058114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diabetic nephropathy: Renoprotective effects of GLP1R agonists and SGLT2 inhibitors.
    Hocher B; Tsuprykov O
    Nat Rev Nephrol; 2017 Dec; 13(12):728-730. PubMed ID: 28989173
    [No Abstract]   [Full Text] [Related]  

  • 26. Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease.
    Li J; Albajrami O; Zhuo M; Hawley CE; Paik JM
    Clin J Am Soc Nephrol; 2020 Nov; 15(11):1678-1688. PubMed ID: 32518100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Network Meta-Analysis of Novel Glucose-Lowering Drugs on Risk of Acute Kidney Injury.
    Zhao M; Sun S; Huang Z; Wang T; Tang H
    Clin J Am Soc Nephrol; 2020 Dec; 16(1):70-78. PubMed ID: 33376101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination Therapy With Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Older Patients With Type 2 Diabetes: A Real-World Evidence Study.
    Carretero Gómez J; Arévalo Lorido JC; Gómez Huelgas R; García de Lucas D; Mateos Polo L; Varela Aguilar JM; Seguí Ripoll JM; Ena J;
    Can J Diabetes; 2019 Apr; 43(3):186-192. PubMed ID: 30415909
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipid Profile Changes Associated with SGLT-2 Inhibitors and GLP-1 Agonists in Diabetes and Metabolic Syndrome.
    Premji R; Nylen ES; Naser N; Gandhi S; Burman KD; Sen S
    Metab Syndr Relat Disord; 2022 Aug; 20(6):321-328. PubMed ID: 35452324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Research digest: pioneering an oral GLP-1 receptor agonist.
    Atkinson MA; Powers AC
    Lancet Diabetes Endocrinol; 2019 Dec; 7(12):897. PubMed ID: 31748168
    [No Abstract]   [Full Text] [Related]  

  • 31. Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints.
    Doumas M; Imprialos Κ; Stavropoulos K; Reklou A; Sachinidis A; Athyros VG
    Curr Pharm Des; 2018; 24(17):1879-1886. PubMed ID: 29865997
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In type 2 diabetes, GLP-1 RA plus SGLT2 inhibitor vs. either drug alone reduces HbA
    Tanner M
    Ann Intern Med; 2020 Nov; 173(10):JC52. PubMed ID: 33197349
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of glucagon-like peptide-1 receptor agonists on serum uric acid concentration: A systematic review and meta-analysis.
    Najafi S; Bahrami M; Butler AE; Sahebkar A
    Br J Clin Pharmacol; 2022 Aug; 88(8):3627-3637. PubMed ID: 35384008
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Choosing GLP-1 receptor agonists or SGLT-2 inhibitors by cardiorenal risk.
    Bailey CJ
    Lancet Diabetes Endocrinol; 2020 Feb; 8(2):97-99. PubMed ID: 31843565
    [No Abstract]   [Full Text] [Related]  

  • 35. Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis.
    Global Health & Population Project on Access to Care for Cardiometabolic Diseases (HPACC)
    Lancet Diabetes Endocrinol; 2021 Dec; 9(12):825-836. PubMed ID: 34656210
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the Impact of SGLT2-Inhibitors and Exenatide on Body Fat Composition.
    Agcakaya E; Mutlu HH; Erbakan A; Sargin M
    J Coll Physicians Surg Pak; 2023 Mar; 33(3):308-313. PubMed ID: 36945162
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of Race and Ethnicity With Prescription of SGLT2 Inhibitors and GLP1 Receptor Agonists Among Patients With Type 2 Diabetes in the Veterans Health Administration System.
    Lamprea-Montealegre JA; Madden E; Tummalapalli SL; Peralta C; Neilands TB; Garcia PK; Muiru A; Karliner L; Shlipak MG; Estrella MM
    JAMA; 2022 Sep; 328(9):861-871. PubMed ID: 36066519
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The year in cardiovascular medicine 2021: diabetes and metabolic disorders.
    Cosentino F; Bhatt DL; Marx N; Verma S
    Eur Heart J; 2022 Jan; 43(4):263-270. PubMed ID: 34974614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The comparative cardiovascular and renal effectiveness of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A Scandinavian cohort study.
    Ueda P; Wintzell V; Dahlqwist E; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Melbye M; Hviid A; Svanström H; Pasternak B
    Diabetes Obes Metab; 2022 Mar; 24(3):473-485. PubMed ID: 34738703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sodium Glucose Transporter, Type 2 (SGLT2) Inhibitors (SGLT2i) and Glucagon-Like Peptide 1-Receptor Agonists: Newer Therapies in Whole-Body Glucose Stabilization.
    Shepard BD; Ecelbarger CM
    Semin Nephrol; 2021 Jul; 41(4):331-348. PubMed ID: 34715963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.